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This  meeting,  a  joint  event  of  Cold  Spring  Harbor 
Labora  tory (CSHL) and the Wellcome Trust and funded 
in  part  by  the  National  Institute  of  General  Medical 
Sciences (NIGMS), brings together scientists from many 
disciplines,  from  basic  genomics  to  clinical  medicine. 
They share a common interest in understanding the role 
of  inherited  variation  in  drug  response  phenotypes 
ranging  from  life  threatening  adverse  drug  reactions 
(ADRs)  to  lack  of  the  desired  therapeutic  drug  effect. 
Pharmacogenomics  is  a  major  component  of  the 
movement  toward  personalized  or  individualized  medi­
cine.  This  year,  in  addition  to  prominent  examples  of 
pharmacogenomic research, the meeting heard contribu­
tions  on  state­of­the­art  next­generation  sequencing, 
genome­wide  analyses,  genetic  control  of  expression, 
epigenetics, and translational bioinformatics, comple  men­
ted by presentations on ethical, legal, and societal issues. 
There were more than 130 international participants.
Future scope of genomic medicine and key 
discoveries in pharmacogenomics
The  keynote  lectures  of  the  opening  sessions  were 
dedicated  to  the  exploration  of  the  future  potential  of 
pharmacogenomic applications in health care based on 
past and current developments. Eric D Green, Director of 
the  National  Human  Genome  Research  Institute 
(NHGRI, Bethesda, USA), laid out the opportunities of 
the  human  genome  sequence  for  genomic  medicine 
(described as ‘from base pairs to bedside’). The path of 
realization faces bottlenecks at many levels, but these can 
be  overcome  using  techniques  including  functional 
genomic analysis (such as comparative genome sequencing 
and  epigenetic  landscaping),  elucidation  of  human 
genomic variation (such as the HapMap Project and the 
1000 Genomes Project), and identification of the genomic 
basis for rare monogenetic and common complex human 
disease  (such  as  genome­wide  association  studies 
(GWASs)  and  post­GWAS  approaches).  Because  the 
costs  have  become  affordable,  we  can  now  perform 
routine whole­genome sequencing of individual human 
genomes. Yet the next­generation sequencing techniques 
will produce enormous amounts of sequence data that 
will  require  complex  computational  analyses  and 
thorough interpretation of genomic information. Green 
presented a strategic plan of breaking down the tasks into 
five genomic domains, which will aid efforts to overcome 
current  and  future  bottlenecks  (Figure  1).  For  timely 
progress,  this  strategic  plan  should  be  revisited  and 
refined every 5 years.
Pharmacogenetic  markers  and  how  they  were  dis­
covered  were  presented  by  Michel  Eichelbaum  (Dr 
Margarete  Fischer­Bosch­Institute  of  Clinical  Pharma­
cology, Stuttgart, Germany). He highlighted prominent 
examples  following  a  historic  tour  from  the  first 
pharmaco  genetic  trait  at  the  beginning  of  the  era  of 
pharmacogenomics ­ the observation of the occurrence 
of hemolysis/death in relation to fava bean consumption 
in  Mediterranean  populations  3,000  years  ago  and  its 
mechanistic  explanation  in  modern  times  ­  to  the 
discovery  by  Beutler,  Waller  and  Löhr  in  1956­7  of 
sensitivity to an antimalarial drug (primaquine) related to 
glucose  6­phosphate  dehydrogenase  deficiency.  Some 
more recent examples are shown in Table 1. In the past 
35  years,  characterization  of  loss  of  function  of  drug 
metabolizing enzymes ­ including Eichelbaum’s work on 
the  cytochrome  P450  (CYP)  2D6  poor  metabolizer 
phenotype ­ has led to the understanding of the profound 
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© 2011 BioMed Central Ltdeffects  of  inherited  differences  in  drug  metabolizing 
enzymes on the pharmacokinetics of a drug. Such differ­
ences  can  result  in  more  than  a  100­fold  difference  in 
systemic drug exposure, with clinically important effects 
on  drug  response.  Today,  it  is  recognized  that  trans­
porters, receptors, and genes of signaling pathways are 
Figure 1. A strategic plan to achieve the goal of genomic medicine (‘base pairs to bedside’). The scheme illustrates past and current 
accomplishments as well as future tasks in the five domains of genomic medicine, also embracing cross cutting elements: bioinformatics 
and computational biology, education and training, and genomics and society. Solid lines indicate major ongoing or expected activities and 
accomplishments across the domains at respective time intervals. Dashed lines indicate fewer activities, respectively.
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Table 1. Examples of implementation of pharmacogenetics for the improvement of drug response and avoidance of 
adverse drug reactions
  Marker and     
Drug  genetic variants  Treatment application  Drug effect and risks
Tamoxifen  CYP2D6; PM alleles   Breast cancer  Prodrug that requires conversion into active metabolite 
  *3, *4,*5, *6 and *7    (endoxifen); PM patients have a higher risk of developing  
      recurrence than EM patients; CYP2D6 polymorphism explains  
      38 to 69% of variable plasma endoxifen levels
Warfarin  CYP2C9; VKORC1   Prevention of thrombo-embolic   Increased risk of thrombo-embolic events at INR <2 to 3;  
    events; maintenance dose is critical   increased risk of bleeding at INR >2 to 3; drug is the largest 
    (INR 2-3)  cause of AEs and hospital emergency room visits 
Clopidogrel  CYP2C19*2  Cardiovascular medicine to prevent   Increased risk of cardiovascular event; explains 12% of 
    platelet aggregation  variability
Abacavir  HLA-B*5701  AIDS  5% of patients develop hypersensitivity (fever, skin rash,  
      gastro-intestinal symptoms, or eosinophilia); genotyping  
      before therapy reduces incidence of hypersensitivity and is  
      cost effective
Flucloxacillin,   HLA-B*5701  Bacterial infections; β-lactam  20% of DILI-related hospitalizations 
amoxicillin-clavulanate     antibiotics 
Simvastatin  OATP1B1*5  Control of elevated cholesterol   Increased risk of myopathy 
    (hypercholesterolemia)  
Cisplatin  TPMT, COMT  Chemotherapy   Permanent, bilateral hearing loss (grade 2-4) in 10 to 25% of  
      adult patients and 41 to 61% of children 
AE, adverse event; AIDS, acquired immune deficiency syndrome; COMT, catechol-O-methyl transferase; CYP, cytochrome P450; DILI, drug-induced liver injury; EM, 
extensive metabolizer; HLA-B, human leukocyte antigen B; INR, international normalized ratio; OATP, organic anion transporting polypeptide; PM, poor metabolizer; 
TPMT, thiopurine S-methyltransferase; VKORC, vitamin K, epoxide reductase complex.
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understood that genetic factors account for 20 to 95% of 
the  variability  in  drug  disposition  (that  is,  absorption, 
distribution,  metabolism  and  excretion)  and  effects; 
however, pharmacogenomic testing is not about a yes or 
no answer but about probabilities that a response/event 
occurs.  Drug  effects  (response,  resistance,  and  ADRs) 
cannot be explained by single genes or variants but are 
under the influence of multiple genetic and non­genetic 
factors  (such  as  age,  sex,  body  mass  index  and  organ 
function). The identification of clinically useful markers 
therefore  requires  large  pharmacogenomic  studies  with 
phenotypically  well  characterized  study  subjects, 
comprehensive allele coverage for the genetic description 
of these phenotypes, and consideration of confounders 
(such as drug adherence and co­medications).
Innovations in genomic biology and implications 
for pharmacogenomics
Deborah A Nickerson (University of Washington School 
of  Medicine,  Seattle,  USA)  highlighted  the  finding  of 
new genetic variants and genetic signatures for diseases 
identified  by  exome  sequencing.  The  complete  set  of 
exons (including splice sites and microRNAs) ­ referred 
to  as  the  ‘exome’  ­  makes  up  only  1%  of  the  human 
genome. By selecting the exome to sequence, important 
information  about  an  individual  can  be  obtained  at  a 
much lower cost than would be required for sequencing 
their entire genome. Assessment of the results of exome 
sequencing is based on knowledge of the genetic code 
and allows a more informative interpretation of genetic 
variants. Rare variants that typically provide a stronger 
indication of disease susceptibility can be detected. As a 
result  of  the  sequencing  of  1,000  exomes  more  than 
360,000  novel  variants  have  been  identified,  half  of 
which change the resulting amino acid sequences. For 
example,  examining  CYP2C9  among  1,000  genomes 
revealed considerably more variants than those reported 
in public databases. Some of these result in amino acid 
changes  at  substrate  binding  sites,  which  means  that 
exome  sequen  cing  could  be  highly  relevant  for 
pharmacogenomics discoveries.
The genetic control of drug response was addressed by 
David  B  Goldstein  (Duke  University,  Durham,  USA) 
using the example of variable response to drug treatment 
(pegylated  interferon  and  ribavirin)  of  hepatitis  C.  He 
outlined  discovery  strategies  for  pharmacogenomic 
ques  tions  and  reported  on  the  determination  of  drug 
efficacy  by  analyzing  sustained  virological  response 
rates.  An  association  between  sustained  virological 
response and the variant rs12979860 of the interferon 
(IFN)λ­encoding gene IL-28B was identified by GWAS. 
There was inter­ethnic variation in the allele frequency 
of the pro  tective reference allele (African Americans < 
Hispanic  <  Caucasians  <  East  Asians).  Although  no 
biological function is known, poor treatment responders 
have higher blood levels of expression of IFN­responsive 
genes.  Likewise,  GWASs  identified  an  association 
between an ADR (severe anemia) and the chromosome 
20q13  region.  A  functional  interpretation  is  possible 
through a neighboring gene encoding an enzyme of ATP 
synthesis  (ITPA),  which  contains  two  functional 
variants.  Addressing  the  implications  for  diagnostic 
utility,  drug  development  and  evaluation,  mechanistic 
insights, and control of sources of variability in clinical 
trials,  Goldstein  emphasized  that  although  many  drug 
responses are influenced by genetic variants, they cannot 
always  directly  be  detected  by  GWASs  but  require 
further in­depth analysis.
The putative role of the transcriptome for pharmaco­
genomics was addressed by Thomas Gingeras (CSHL). 
He reported that eukaryotic transcriptomes are far from 
being understood because information stored in DNA 
sequences is complex, layered, and compartmentalized. 
Thus, the genome has to be re­annotated because of a 
growing number of newly identified transcripts, not only 
non­coding but also coding. He presented data from the 
Sanger  Institute  and  ENCODE  transcriptome  projects 
based on deep sequencing and tiling array analyses of 
transcriptomes  of  various  cell  lines  and  tissues  of 
multiple  organisms.  Subfractionation  of  cells  enriches 
for  certain  RNA  groups,  resulting  in  the  detection  of 
new  RNAs  and  RNA  isoforms.  The  genome  can  be 
regarded as being much richer than currently thought 
because  regions  are  interconnected  and  littered  with 
start sites, with many functional elements on top of each 
other.  Thus,  a  gene  represents  a  ‘coding/non­coding 
cluster in the genome’, which serves as a template for up 
to  eight  transcripts.  This  refined  view  of  unique 
transcriptomes  should  be  applied  to  gaining  a  better 
understanding of gene regulation and its possible role in 
disease and drug response.
Copy  number  variants  (CNVs)  account  for  a  major 
proportion of human genetic polymorphisms and they 
may have an important role in genetic susceptibility to 
human disease. Peter J Donnelly (Wellcome Trust Centre 
for Human Genetics, Oxford, UK) reported on a large 
genome­wide study of the Wellcome Trust Case Control 
Consortium  (WTCCC)  for  the  investigation  of 
associations between CNVs and eight common diseases 
(16,000  patients  ­  2,000  with  each  of  bipolar  disorder, 
breast cancer, coronary artery disease, Crohn’s disease, 
hypertension, rheumatoid arthritis, type 1 diabetes, and 
type 2 diabetes). They used an array targeting more than 
11,700  CNVs,  each  detected  by  ten  probes,  and  only 
3,000  CNVs  passed  quality  control.  Although  a  small 
number  of  CNVs  were  found  to  be  associated  with 
Crohn’s disease, type 2 diabetes, and breast cancer, these 
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SNPs, from which it follows that CNVs cannot explain 
much  of  the  missing  heritability  of  common  diseases. 
More  over, analytical challenges in CNV studies include 
varying  results  attributable  to  different  DNA  sources 
(blood  versus  B  cell  lines)  and  observed  high  false­
negative  rates  from  comparative  CNV  associations 
generated from SNP chips (Affymetrix versus Illumina 
platforms). Thus, CNV findings from case­control studies 
must be interpreted with care.
One  of  us  (ME)  explained  the  role  of  epigenetics  in 
personalized  medicine,  particularly  in  oncology.  He 
described that the contribution of DNA methylation and 
histone modifications, the two main epigenetic layers, to 
this area could be subdivided into epigenetic markers to 
predict  drug  sensitivity  (pharmacoepigenetics)  and 
genetic markers to predict response to epigenetic drugs 
(such as DNA demethylating agents and histone deace­
tylase inhibitors). The best example of pharmacogenetics 
is the prediction of good response to the chemotherapy 
drugs temozolomide and carmustine in gliomas in which 
there  is  silencing  of  the  DNA  repair  enzyme  O6­
methylguanine­DNA  methyltransferase  (MGMT)  asso­
cia  ted  with  promoter  CpG  island  hypermethylation. 
Further examples included the epigenetic inactivation of 
the Werner gene and response to irinotecan in colorectal 
cancer. Recent results from his group have demonstrated 
that hypermethylation of the BRCA1 breast cancer gene 
CpG island is a marker of good response to poly ADP­
ribose  polymerase  (PARP)  inhibitors  in  breast  cancer 
cells. This finding might significantly increase the number 
of breast cancer patients that could benefit from these 
therapies  outside  the  high­risk  inherited  forms  of  the 
disease. He also showed that the genes involved in the 
epigenetic machinery, such as DNA methyltransferases 
and histone modifiers, can also undergo genetic changes 
related  to  differential  sensitivity  to  epigenetic  drugs. 
Examples of genetic amplification, deletion, and mutation 
of  these  genes  are  described  in  the  literature,  and  a 
frameshift  mutation  in  the  histone  deacetylase  2 
(HDAC2)  gene  is  associated  with  resistance  to  histone 
deacetylase  inhibitors.  Emerging  research  in  the 
genomics  and  epigenomics  arena  will  provide  us  with 
new epigenetic candidates for the personalized treatment 
of human malignancies.
The role of bioinformatics in pharmacogenomics
Steven  E  Brenner  (University  of  California,  Berkeley, 
USA)  showed  the  long­term  exponential  growth  of 
sequence  data  and  its  recent  disruptive  increase  in 
growth. His experience of RNA splice regulation using 
RNA sequencing technology showed that the majority of 
alternative  splicing  events  contain  previously  unanno­
tated  exonic  structures;  he  extrapolated  from  this  to 
highlight the great potential of using the vast amounts of 
sequence  data  in  the  emerging  field  of  pharmaco­
transcriptomics.  The  talk  introduced  a  community 
experi  ment  to  evaluate  computational  methods  for 
pheno  type  prediction  based  on  genomic  variation  (the 
Critical  Assessment  of  Genome  Interpretation,  CAGI: 
http://genomeinterpretation.org),  modeled  on  the 
Critical  Assessment  of  Structure  Prediction  (CASP) 
exercise  for  protein  structure  prediction.  There  is  an 
urgent need to interpret the multitude of variations in 
expression, allele­specific expression, splicing, transcript 
structure, and common and rare exonic variants. Dozens 
of prediction algorithms exist for this purpose, but their 
utility  is  not  well  understood.  The  CAGI  experiment 
presented  a  number  of  datasets  for  the  prediction  of 
phenotypic consequences, including a pharmacogenomic 
dataset of over 50 breast cancer cell lines exposed to over 
50 different drugs that will be relevant for the prediction 
of drug response. Within the personal genome project 
the genomes of ten individuals are being investigated for 
the  prediction  of  50  health­  and  disease­related 
phenotypes.  CAGI  ultimately  had  over  100  prediction 
submissions from seven countries. CAGI aims to under­
stand the diversity of mechanisms of genome variation, 
identify  bottlenecks  in  genome  interpretation,  inform 
critical areas of future research, and connect researchers 
from diverse disciplines whose expertise is essential to 
methods for genome interpretation.
Ethical, economical and societal aspects of 
pharmacogenomics
The cost­effectiveness of pharmacogenomics with respect 
to challenges and opportunities in an era of decreasing 
test costs was addressed by David L Veenstra (University 
of Washington, Seattle, USA). A stated lack of evidence 
of clinical utility is a frequent reason for health insurers 
to  refuse  to  reimburse  patients  for  pharmacogenomic 
testing. To better assess such evidence, the Evaluation of 
Genomic  Applications  in  Practice  and  Prevention 
(EGAPP) initiative is developing a systematic process to 
capture the validity and utility of emerging genetic tests 
for  clinical  practice.  A  novel  approach,  comparative 
effectiveness research, aims to ensure that much more 
useful data will be collected (as compared with standard 
clinical trials) and better methods developed for under­
standing  the  differences  in  drug  effectiveness  among 
different patient groups, such as risk­benefit modeling. 
Lastly, the value of conducting additional research should 
be weighed against the cost of conducting such research 
using quantitative value of research analyses.
Future trends in pharmacogenomics
Integrated  presentations  from  pharmacologists  and 
human  genome  biologists  highlighted  the  incredible 
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optimizing  drug  therapy.  Rapid  advances  in  genomic 
technologies  are  being  quickly  adopted  by  pharmaco­
genomics researchers and will fuel progress in this area. 
The overarching need for the collection of large numbers 
of  well  phenotyped  drug­treated  populations  was  a 
central theme of most presentations, as were the diffi­
culties associated with identifying appropriate replication 
cohorts. Future advances in human genomics and their 
application to pharmacogenomics are expected to bring 
continued advances to this important area of translational 
medicine.
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